{"filing":{"accession_number":"0001654954-26-008234","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"a1355u.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426008234/a1355u.htm"},"events":[{"id":32474,"run_id":29837,"accession_number":"0001654954-26-008234","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GSK announced Japan's Ministry of Health, Labour and Welfare approval of a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine). This is a regulatory milestone and product formulation approval that expands the commercial availability of an existing vaccine in a major market. While not a discrete M\u0026A, earnings event, or executive change, it represents a material operational and commercial development—a new product presentation launch in Japan following earlier US and European launches—that would affect a reasonable investor's assessment of GSK's vaccine portfolio expansion and market reach.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":35659,"accession_number":"0001654954-26-008234","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"GSK announced Japan's Ministry of Health, Labour and Welfare approval of a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine). This is a regulatory milestone and product formulation approval that expands the commercial availability of an existing vaccine in a major market. While not a discrete M\u0026A, earnings event, or executive change, it represents a material operational and commercial development—a new product presentation launch in Japan following earlier US and European launches—that would affect a reasonable investor's assessment of GSK's vaccine portfolio expansion and market reach.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:09:37.143773+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-10"}]}